Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!

Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo. Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications. However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.